$PBIO South Easton, MA, Sept. 26, 2019 (GLOBE NEWS
Post# of 7619
(Total Views: 75)
Posted On: 09/30/2019 3:02:29 PM
$PBIO South Easton, MA, Sept. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pressure BioSciences, Inc. (PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that the Company’s patented pressure cycling technology (“PCT”) platform was prominently featured in no less than ten separate presentations from scientists affiliated with seventeen leading research institutions worldwide at the International Human Proteome Organization World Congress (“International HUPO”), held this year from September 15-18, 2019 in Adelaide, Australia.
International HUPO plays a pivotal role in defining and promoting proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques, and training to better understand the full complement and roles of proteins in human health and disease. The multiple PCT-related presentations included development of new methods and applications using PBI’s unique PCT platform to advance knowledge and understanding in areas such as cancer research, with particular focus on cancer biomarker discovery.
Ms. Roxana McCloskey, PBI's Global Director of Sales & Marketing, commented: "We are delighted to note that the number of PCT-related presentations at important international meetings is now exploding, in response to our years of investment in building collaborations and supporting research and the publication of now over 150 peer-reviewed scientific articles. Most importantly, several presentations describe new workflows, applications, and techniques for the PCT platform that were developed independently by scientists from many different prestigious institutions. We believe that several of the methods described will eventually lead to the routine use of the PCT platform in clinical diagnostics and precision medicine, a market that is expected to reach $217 billion by 2028 (BIS Research, 2019).”
PCT-related presentations delivered at this meeting were primarily in the key areas of new and approved methods and protocols and in new applications for the discovery and identification of cancer markers. The presentations continue to show the flexibility and increasing potential for the PCT platform in cancer diagnostics and discovery.
https://www.marketwatch.com/press-release/net...quote_news
International HUPO plays a pivotal role in defining and promoting proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques, and training to better understand the full complement and roles of proteins in human health and disease. The multiple PCT-related presentations included development of new methods and applications using PBI’s unique PCT platform to advance knowledge and understanding in areas such as cancer research, with particular focus on cancer biomarker discovery.
Ms. Roxana McCloskey, PBI's Global Director of Sales & Marketing, commented: "We are delighted to note that the number of PCT-related presentations at important international meetings is now exploding, in response to our years of investment in building collaborations and supporting research and the publication of now over 150 peer-reviewed scientific articles. Most importantly, several presentations describe new workflows, applications, and techniques for the PCT platform that were developed independently by scientists from many different prestigious institutions. We believe that several of the methods described will eventually lead to the routine use of the PCT platform in clinical diagnostics and precision medicine, a market that is expected to reach $217 billion by 2028 (BIS Research, 2019).”
PCT-related presentations delivered at this meeting were primarily in the key areas of new and approved methods and protocols and in new applications for the discovery and identification of cancer markers. The presentations continue to show the flexibility and increasing potential for the PCT platform in cancer diagnostics and discovery.
https://www.marketwatch.com/press-release/net...quote_news
(0)
(0)
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Scroll down for more posts ▼